Phase I/II safety and antitumor activity of nivolumab in patients with advanced HCC

ntitumor activity and safety of pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (KEYNOTE-012)

Phase III, randomized trial (CheckMate 057) of nivolumab vs. docetaxel in advanced non-squamous cell NSCLC

PD-1 Blockade in Tumors with Mismatch Repair Deficiency

SIRIUS, a phase II study of daratumumab monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma

Ibrutinib combined with bendamustine and rituximab in previously treated CLL/SLL

GADOLIN: a phase III study of obinutuzumab plus bendamustine vs. bendamustine in rituximab-refractory non-Hodgkin lymphoma

PERSIST-1 phase III study of pacritinib vs. best available therapy in myelofibrosis

A phase III protocol of docetaxel and prednisone, the first effective adjuvant chemotherapy for high-risk, localized prostate cancer

Extensive lymph node surgery may not be necessary for all melanoma patients

Randomized, open-label, multicenter, phase III study of eribulin vs. dacarbazine in leiomyosarcoma and adipocytic sarcoma

Anastrazole offers higher breast cancer-fee survival rates than tamoxifen following DCIS in postmenopausal patients

PALOMA3: a double-blind, phase III trial of palbociclib in HR+, HER2- metastatic breast cancer that progressed on endocrine therapy

Reduction in late mortality among 5-year survivors of childhood cancer

Elective vs. therapeutic neck dissection in the clinically node negative early oral cancera

Phase III randomized trial of whole brain radiation therapy in addition to radiosurgery in patients with 1 to 3 brain metastases

US on first data with nivolumab in patients with advanced HCC

Illumination and Innovation: Transforming Data into Learning

Expert on novelties of immunotherapy at ASCO2015

Mismatch repair deficiency predicts pembrolizumab response in colorectal cancer

Pembrolizumab in patients with advanced squamous cell carcinoma of the head & neck

CheckMate 057 trial of nivolumab vs. docetaxel in advanced non-squamous cell NSCLC

Scientific novelties of ASCO2015

PERSIST-1 study of pacritinib versus best available therapy in myelofibrosis

GADOLIN: a phase III study of obinutuzumab in rituximab-refractory non-Hodgkin lymphoma

Bruton’s tyrosine kinase ibrutinib in previously treated CLL/SLL

Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer (PALOMA3 study)

CheckMate 067: Phase III trial of nivolumab ± ipilimumab vs. ipilimumab alone in treatment-naive patients with advanced melanoma

ASCO2015 melanoma trial results

ASCO2015 with the eye of a melanoma expert

ASCO2015 novelties in treatment of prostate cancer